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Abstract
Background: Some of the studies confirmed the effectiveness of platelet rich plasma (PRP) in the treatment of diabetic foot ulcers
(DFU). However, these studies had small sample size and used different methods such as PRP gel or PRP injections. The results are
also contraversial.
Objectives: This study aimed to investigate the effect of PRP dressing on healing of DFUs.
Patients and Methods: A randomized, controlled trial was conducted on 50 patients with DFUs referred to Kashan’s Shahid Be-
heshti hospital. Patients were randomly allocated to control (n = 25) and experimental (n = 25) groups. Data collection instrument
consisted of two checklists; one for gathering demographic information and the other one included questions about ulcer char-
acteristics and its treatment. After surgical debridement, ulcers depth and surface area were measured. Then, the ulcers of the
control group were irrigated and dressed with sterile gauzes. However, in the intervention group, ulcers were dressed with sterile
gauzes impregnated with PRP. Ulcers depth and surface area of all ulcers were measured on the days 0, 7, 14 and 21 after debridement.
Independent-samples t-test, Mann–Whitney U and repeated measures analysis of variance were used to analyze data.
Results: At baseline, the mean ulcer depth were 15.08± 10.43 and 19.08± 14.01 mm in the control and intervention groups, respec-
tively (P = 0.26), which decreased to 13.03± 14.1 and 4.560± 5.76 after three weeks (P = 0.04). Moreover, the mean ulcer surface area
were 14.17± 8.52 and 12.791± 14.86 mm2 in control and intervention groups respectively (P = 0.69), which decreased to 11.88± 13.65
and 2.68± 5.94 after three weeks (P = 0.03).
Conclusions: PRP dressing could significantly decrease the depth and surface area of DFUs in a three-week period.
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1. Background
Diabetic foot ulcers (DFU) are of the most serious and
costly complications of diabetes (1). Studies in the United
States estimated that each year more than 50000 to 60000
patients with DFUs undergo amputation (2). According to
latest estimates, more than 7 million people with diabetes
live in Iran (3) and 2 - 4% of them have diabetic foot ulcers
(4). Today, management of diabetic foot ulcers is a big chal-
lenge (5). At present, two treatment protocols are used for
these patients. The first method includes decreasing the
pressure on the ulcer, debridement, infection treatment,
managing ischemia and ulcer dressing. The second pro-
tocol involves using high pressure oxygen, negative pres-
sures and artificial skin graft. Although both methods are
costly and time consuming, their effectiveness is not satis-
factory (6). Using platelet-rich plasma (PRP) is one of the
new treatments for diabetic foot ulcers (7).
Most of growth factors affecting ulcer healing are se-
creted by platelets (8, 9). Therefore, vascular disorder
around the diabetic foot ulcer would decrease transfer of
blood cells and platelets to this area and then the speed of
healing would decrease (10). However, it seems that PRP
dressing would increase the level of growth factors and
consequently lead to a faster and better ulcer healing (2).
Nowadays, different forms of platelet products are used in
the treatment of a variety of conditions (11). For instance,
in a prospective, randomized, controlled trial, Driver et al.
used autologous platelet-rich plasma gel for the treatment
of diabetic foot ulcers and reported that PRP gel was effec-
tive and safe for use in the treatment of nonhealing dia-
betic foot ulcers (12). Moreover, in a case report, Mehrannia
et al. reported the effective use of PRP in the treatment of
non-healing DFUs (13). In a small study on six patients, Tran
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et al. used activated PRP in the treatment of DFUs (14).
PRP is also used in many circumstances such as oral,
maxillofacial, orthopedics, plastic and heart surgeries as
well as wound treatment (11). Though using PRP in the
treatment of DFU is very affordable, because it can be pre-
pared from a small blood volume of patient (15). However,
Jeong et al. did not recommend the use of autologous PRP
in patients with anemia and those with unstable clinical
conditions (16). In another study, Scevola et al. used al-
logeneic platelet gel for the treatment of pressure ulcer
and reported that the method was only effective during the
first two weeks of treatment (17). Moreover, in two review
studies, Keshavarzi et al. (4) and Game et al. (18) referred
to many problems in this field and concluded that these
products are not sufficiently effective.
Although several previous studies confirmed the effec-
tiveness of using PRP in the treatment of DFU, these studies
were case reports or had small sample size and used differ-
ent methods such as PRP gel (12) or injections (19) and no
study is available on the use of PRP through simple routine
dressings.
2. Objectives
Due to a formentioned controversies, this study aimed
to investigate the effect of PRP dressing on healing of dia-
betic foot ulcers.
3. Patients andMethods
3.1. Design and Participants
This double blind randomized, controlled clinical trial
was conducted on 50 patients with DFUs referred to
Kashan’s Shahid Beheshti hospital, from July 2014 to April
2015. Sample size was calculated using Kargar et al. inves-
tigation who studied the effect of platelet gel on the treat-
ment of DFU. In that study, post-intervention mean± stan-
dard deviation of the ulcer depth in control and experi-
mental groups were 7.4± 1.6 and 5.3± 1.4, respectively (2).
Accordingly, with a type I error probability of 0.05 and a
power of 0.80, the sample size was determined as seven pa-
tients in each group. However, we recruited 30 experimen-
tal subjects and 30 control subjects to compensate proba-
ble attritions and achieve more reliable results.
Inclusion criteria were being able and willing to par-
ticipate in the study, having a DFU in grades 1 or 2 (accord-
ing to the Wagner classification system for DFU (20) and
based on physicians’ diagnosis), a hemoglobin level of 10
gr/dL and more, platelet count more than 100000 mm3, re-
ceiving no immunosuppressive and contraceptive medica-
tions, having no known coagulopathy, immune deficiency,
cancer, having no signs of ischemia around the ulcer, sep-
sis, osteomyelitis, deep vein thrombosis, limb paralysis,
not receiving chemotherapy and lack of a history of spinal
cord injury and stroke. Patient’s decision to withdraw from
the study and not completing the intervention were the
study exclusion criteria.
After coordination with the hospital authorities, invi-
tation letters were sent to diabetic patients with an active
non-healing DFU to participate in the study. Among 100 pa-
tients who volunteered to participate and examined by a
specialist in infectious diseases, 60 patients with inclusion
criteria were selected and then using a random number
tabulation were allocated into control (n = 30) and inter-
vention groups (n = 30), Figure 1.
3.2. The Instruments
Data collection instrument consisted of two checklists.
The first checklist consisted of questions on demographic
information (i.e. patients’ age, gender, occupation, mar-
ital status, participants, name, living location, residential
address and phone number, income, weight, height, body
mass index (BMI), education level, smoking habit, time
passed from the diagnosis of diabetes, type of diabetes and
the type of medical treatment used). In addition to fasting
blood sugar (FBS) and HbA1c levels at the start of study, the
second checklist included questions about wound charac-
teristics and its treatments (i.e. the wound grade, the num-
ber of wounds, duration of ulcer, and its location, the need
for debridement, need for early change of wound dress-
ings, duration of wound healing, wound area and depth in
frequent assessments during the study).
Content validity of the wound assessment checklist
was confirmed by 5 experts in infectious disease. Reliabil-
ity of the checklist was assessed through inter-observers
method. For this purpose, the checklist was completed for
5 patients with DFU and for every patient by 3 researchers.
Then, the agreement between the three observers was cal-
culated (r = 0.95).
Demographic information was gathered at baseline
and ulcer assessment was performed frequently during a
three-week period.
3.3. The Procedure
3.3.1. Ulcer Assessment
According to the guideline for caring and treatment of
DFUs (21), ulcer depth and surface area in the successive ob-
servations were used as measures for ulcer healing.
After ulcer grading by a specialist, all ulcers were surgi-
cally debrided of necrotic tissues by a surgeon. Then, ulcer
depth and surface area were measured. According to the
guideline for automatic colorimetric calibration of human
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Figure 1. The CONSORT Flow Diagram of Patients in the PRP and Control Groups
wounds (22), a digital camera (Canon power shot A4000IS,
zoom Lens 8× 15, 16 mega pixel) was used to measure the
ulcer surface area. The camera was calibrated by an expert
in photography at the beginning of study and rechecked
occasionally during the study. All photos were taken from
a distance of 30 cm while a transparent, millimeter scaled
ruler was placed near the ulcers. Then, an expert analyzed
all photos using AutoCAD software version 19 (Autodesk,
USA) to calculate ulcer surface area in square millimeters
and the results were documented in the ulcer assessment
checklists.
A sterile blunt metal millimeter scaled measure was
used to determine ulcer depth. For this purpose, the tip of
the metal measure was placed in the deepest point of the
ulcer and then a piece of paper was placed perpendicular
to the measure at the ulcer surface. Then, the measure was
read in millimeters and the result was recorded in the ul-
cer assessment checklists.
Usually wound healing starts in the few first days after
debridement and granulation tissue appears in 5 to 10 days
or within 30 days after initial injury (23). Therefore, we ob-
served and documented wound depth and surface area on
days 0, 7, 14, and 21 after debridement.
3.4. Intervention
After debridement, the wounds of the control group
were irrigated with normal saline and dressed with sterile
gauzes. However, in the intervention group, the debrided
ulcers were dressed with sterile gauzes impregnated with
PRP. For this purpose, a piece of sterile gauze impregnated
with PRP was placed on the ulcer surface and supported
by two pieces of dry sterile gauzes and fixed using cotton
bands. All dressings were changed every other day unless
the signs of infection were observed. In these cases, the
dressing was changed immediately and was documented.
PRP dressing was performed only once at the beginning of
study and subsequent dressings in both groups were per-
formed similarly using normal saline and ordinary sterile
cotton gauzes.
To avoid confounding factors, all patients were advised
not to use any other material on the ulcer and avoid any
dressing change without informing the researcher. All pa-
tients were also instructed about the sings of ulcer infec-
tion and asked to inform the researcher if any signs of in-
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fection occurred. All dressing changes during the study
were performed by the first researcher in hospital or in pa-
tients’ house (if a patient was unable to refer to hospital).
3.5. PRP Preparation
Firstly, a thorough physical examination was per-
formed to rule out anemia and other diseases. Then, us-
ing a sterile 50 mL syringe, 30 mL of whole venous blood
was drawn from each patient to generate 5 mL of PRP
with a concentration of 100000 platelets in mL. The whole
blood was taken in a sterile Falcon tube containing 3 mL
of sodium citrate (to prevent clotting). According to the
guideline of the American association of blood banks (24),
the samples were kept in a laboratory specimen collec-
tion box with inside temperature of 24°C and immediately
transferred to the laboratory. In laboratory, samples were
centrifuged at 200 rpm for 10 minutes (digital full-R5702
model, Eppendorf, Germany). Then, PRP accumulated on
the upper surface of the tube was collected using a sterile
pipette and transferred to another sterile Falcon tube. The
prepared PRP was then kept in the specimen collection box
with inside temperature of 24°C and transferred to hospi-
tal within 30 minutes. At patient’s bedside, autologous PRP
was placed in a sterile stainless receiver containing a ster-
ile cotton gauze to prepare a PRP impregnated gauze to be
applied on debrided DFU.
3.6. Ethical Considerations
This study was approved by the institutional review
board and the ethics committee of Kashan University of
Medical Sciences (approval number: 9321). The research
objectives were explained to all patients and a written in-
formed consent was obtained. All patients were also in-
formed about voluntary participation and the right for
withdrawal at any time. They also were assured that their
anonymity would be protected and their personal infor-
mation would be kept confidential.
3.7. Data Analysis
Data was analyzed using SPSS version 13 (SPSS Inc.
Chicago, IL, USA). The findings were reported via abso-
lute and relative frequency values, mean and standard
deviation (SD). The categorical variables were analyzed
by chi-squazre and Fisher’s exact tests. On the other
hand, variables with interval and ratio measurement scale
were primarily assessed regarding their distribution using
Kolmogorov-Smirnov test. Then, independent-samples t or
Mann-Whitney U test was performed for analyzing these
variables. Finally, the depth and area of DFUs between dif-
ferent measurement time-points were assessed using re-
peated measures analysis of variance. The level of signifi-
cance was set at below 0.05.
4. Results
Overall, five patients in each group were lost from
follow-up and finally 25 patients in each group entered the
analysis. As presented in Table 1, the two groups were not
significantly different for demographic and clinical vari-
ables.
Duration of diabetes mellitus in participants in exper-
imental and control groups were respectively 13.48± 6.93
and 12.08± 6.64 years (P = 0.47). Moreover, the most com-
mon treatment used by participants for blood sugar con-
trol was insulin injection. Clinical outcomes are shown in
Table 2, Figure 2.
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Figure 2. Variations of Ulcers Depth and Area in Both Study Groups
The frequency of complete wound healing after one
month of treatments in the experimental and control
groups were 36% and 40%, respectively (OR = 13.5, CI 95% =
1.56 - 117.14, and P = 0.005).
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Table 1. Demographic, Laboratory and Clinical Characteristics of Patients in PRP and
Simple Dressing Groupsa
Characteristics Group P Value
PRP Dressing Simple Dressing
Gender 0.51b
Male 20 (80.0) 18 (72.0)
Female 5 (20.0) 7 (28.0)
Location of residence 0.51b
City 20 (80.0) 18 (72.0)
Village 5 (20.0) 7 (28.0)
Economic State 0.93b
Low 8 (32.0) 8 (32.0)
Middle 11 (44.0) 12 (48.0)
High 6 (24.0) 5 (20.0)
Education 0.74b
Illiterate 7 (28.0) 5 (20.0)
Elementary
school
7 (28.0) 7 (28.0)
Intermediate 7 (28.0) 6 (24.0)
High school or
university
4 (16.0) 7 (28.0)
Marriage 0.05c
Married 24 (96.0) 18 (72.0)
Single 1 (4.0) 7 (28.0)
Smoking 0.49c
Yes 2 (8.0) 0 (0)
No 23 (92.0) 25 (100)
BodyMass Index 0.65b
< 18.5 1 (4.0) 2 (8.0)
18.5 - 25 9 (36.0) 11 (44.0)
> 25 15 (60.0) 12 (48.0)
Type of diabetes 0.35c
Type I 24 (96.0) 21 (84.0)
Type II 1 (4.0) 4 (16.0)
Drugs > 0.99c
Insulin 21 (84.0) 20 (80.0)
Oral agents 4 (16.0) 5 (20.0)
Fasting Blood Sugard 257.32± 95.06 216.20± 56.30 0.07e
HbA1Cd 8.38± 1.03 7.86± 0.88 0.06e
aValues are expressed as No. (%) unless otherwise indicated.
bChi-square test.
cFisher’s exact test.
dValues are expressed as mean± SD.
eIndependent t-test.
5. Discussion
This study showed that PRP dressing could signifi-
cantly increase the rate of healing of DFUs, so that both
outcome variables (i.e. the mean depth and surface area of
ulcers) were significantly decreased three weeks after us-
ing PRP dressing in the intervention group. However, nei-
ther the ulcer depth nor the ulcer surface area of the con-
trol group changed significantly during the study. Our re-
sults are consistent with the findings of Driver et al. (12)
who studied the effect of autologous PRP gel in the treat-
ment of DFUs. Moreover, Lacci and Dardik showed the ef-
fectiveness of PRP on wound healing. Although, the heal-
ing time in the Lacci and Dardik study (15) was longer than
that of the present study. Mehrannia et al. reported a sin-
gle case of non-healing DFU that was successfully treated
by injection of PRP inside and around the peripheral skin
(13). Moreover, Tran et al. reported six cases of DFU that
completely closed 7 weeks after two injections of PRP at the
wound bed (14). Conversely, in another study, Maghsoudi
et al. reported that platelet dressing could not enhance
healing of burn wounds (25). Horn et al. reported that al-
though PRP gel could effectively decrease the width and
depth of chronic wounds, changes were not statistically
significant compared with a control group (26). Although
PRP has been used effectively in several conditions such as
dental and oral surgeries (27) and in the treatment of mus-
culoskeletal injuries (19), few human studies are available
on its usage in DFUs. Despite controversies, the present
study confirmed the effectiveness of PRP in the treatment
of DFUs.
Despite many advances in the treatment of DFUs, many
diabetic patients are yet living with this destructive com-
plication (12). Lack and malfunction of some growth fac-
tors disrupt the natural healing process in diabetic pa-
tients, which leads to DFUs. It seems that PRP provides the
growth factor needed for healing (28). It is reported that
seven fundamental protein growth factors that are actively
secreted by platelet initiate wound healing process. PRP
also includes three proteins in blood known to act as cell
adhesion molecules: fibrin, fibronectin and vitronectin
(29). Platelets also secrete transforming growth factor-Beta
(TGF-Beta) and Monocyte Chemoattractant Protein-1 (MCP-
1) that would attract monocytes and neutrophils to the
wound site (28).
Our findings supported that PRP can facilitate healing
of DFUs and therefore can reduce the risk of amputation
(2). Autologous PRP can be prepared easily and does not
need a large volume of patient’s blood. Therefore, its usage
is economical and affordable, and as it is autologous, the
risk of transmission of blood borne diseases is diminished.
PRP preparation in the present study did not change
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Table 2. Ulcer Characteristics
Variable Time Mauchly’s Test Time Time×Group
FirstWeek SecondWeek End
Surface Area,mm2 < 0.001 0.001 0.08
PRP dressing Group 6.98± 9.82 5.10± 8.48 2.68± 5.94
Simple dressing Group 13.22± 9.35 12.32± 11.01 11.88± 13.65
Depth,mm < 0.001 < 0.001 0.01
PRP dressing Group 9.91± 7.39 5.40± 6.05 4.56± 5.76
Simple dressing Group 16.86± 10.19 16.51± 11.56 13.03± 14.10
biochemical composition of plasma, which is considered
as its advantage. Moreover, PRP dressing used in the
present study is a noninvasive method and seems to be
more safe and affordable than methods used in previous
studies (i.e. PRP gel or injection method). PRP gel is usu-
ally prepared from bovine plasma and therefore may cause
allergic reactions. PRP injection method may also put pa-
tients at risk of injection related complications (19, 30).
Lack of control over some confounding factors such as
patients’ nutrition, activities and their level of adherence
to their medical treatments can be considered as some lim-
itations of the present study. Moreover, the study was con-
ducted on a small sample. Therefore, replication of study
with larger sample sizes is recommended.
This study revealed that PRP dressing could signifi-
cantly decrease the depth and surface area of DFUs in a
three-week period. None of the patients receiving PRP de-
veloped any side effects. Therefore, using PRP in the treat-
ment of DFUs is recommended. In this study we used a PRP
with concentration of 100000 platelets per mL. More stud-
ies with different concentrations of PRP, in periods longer
than this study and using PRP after amputation are sug-
gested.
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